 Dideoxynucleosides
"Dideoxynucleosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription.
| Descriptor ID |
D015224
|
| MeSH Number(s) |
D13.570.230.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dideoxynucleosides".
Below are MeSH descriptors whose meaning is more specific than "Dideoxynucleosides".
This graph shows the total number of publications written about "Dideoxynucleosides" by people in this website by year, and whether "Dideoxynucleosides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dideoxynucleosides" by people in Profiles.
-
Bolduc P, Roder N, Colgate E, Cheeseman SH. Care of Patients With HIV Infection: Antiretroviral Drug Regimens. FP Essent. 2016 Apr; 443:23-30.
-
Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010 Oct 15; 51(8):963-72.
-
Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009 May 1; 51(1):20-8.
-
Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2008 Apr-Jun; 7(2):121-9.
-
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7; 358(6):568-79.
-
Jacobs AH, Rueger MA, Winkeler A, Li H, Vollmar S, Waerzeggers Y, Rueckriem B, Kummer C, Dittmar C, Klein M, Heneka MT, Herrlinger U, Fraefel C, Graf R, Wienhard K, Heiss WD. Imaging-guided gene therapy of experimental gliomas. Cancer Res. 2007 Feb 15; 67(4):1706-15.
-
Keiser P, Nassar N, Skiest D, Andrews C, Yazdani B, White A, Hetherington S. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. Int J STD AIDS. 2003 Jul; 14(7):478-81.
-
Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, Back D. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):45-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|